The effects of probiotics, prebiotics and synbiotics on the reduction of IBD complications, a periodic review during 2009â��2020 by Darb Emamie, A. et al.
REVIEW ARTICLE
The effects of probiotics, prebiotics and synbiotics on the
reduction of IBD complications, a periodic review during
2009–2020
A. Darb Emamie1, M. Rajabpour1, R. Ghanavati2, P. Asadolahi3, S. Farzi4, B. Sobouti5 and
A. Darbandi6,7
1 Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2 Behbahan Faculty of Medical Sciences, Behbahan, Iran
3 Microbiology Department, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran
4 Department of Microbiology, Faculty of Medicine, Shahed University, Tehran, Iran
5 Burn Research Center, Iran University of Medical Sciences, Tehran, Iran
6 Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
7 Microbial Biotechnology Research Centre, Iran University of Medical Sciences, Tehran, Iran
Keywords
probiotics, inflammatory bowel disease,
synbiotic, ulcerative colitis, Crohn’s disease,
5-ASA compounds.
Correspondence
Atieh Darbandi, Department of Microbiology,
School of Medicine and Microbial Biotechnol-
ogy Research Centre, Iran University of Medi-
cal Sciences, Shahid Hemmat Highway,
Tehran, Iran.
E-mail: atiehdarbandi86@gmail.com
2020/1852: received 1 September 2020,




Aims: To perform a systematic review on randomized controlled trials to
examine the efficacy of probiotics, prebiotics and synbiotics in the treatment of
IBD.
Methods and Results: PubMed, Web of science, Scopus and Google Scholar
were systematically searched from January 2009 to January 2020 using the
following keywords: ‘Inflammatory Bowel Disease’, ‘Probiotics’ and ‘Clinical
trial’. The statistical analysis was performed using SPSS software version 24.0.
A total of 1832 articles were found during the initial search and 21 clinical
trials were eligible. Studies comparing the effects of probiotics and placebo
among patients with active ulcerative colitis (UC) showed a significant
difference in clinical outcomes. Moreover, probiotics improved the overall
induction of remission rates among patients with Crohn’s disease (CD).
Probiotics significantly decreased the IL-1b, TNF-a and IL-8 levels. Also, the
need for systemic steroids, hospitalization, surgery, as well as histological score
and disease activity index significantly decreased in patients who used probiotic
or pro-/synbiotics.
Conclusions: The use of probiotics, as food supplements, can induce anti-
inflammatory reactions, balance the intestinal homeostasis and induce
remission in IBD. The efficacy of probiotics on remission induction is more
reported in UC rather than CD. Larger well-designed clinical trials are needed
to further determine whether probiotics are of clear benefits for remission in
IBD.
Introduction
Inflammatory bowel disease (IBD) is a chronic relapsing
inflammatory disorder which comprises the two condi-
tions: ulcerative colitis (UC) and Crohn’s disease (CD)
(Matsuoka and Kanai 2015). CD and UC differ by the
intestinal localization and features of the inflammation.
Totally, CD inflammation occurs in the gastrointestinal
tract, whereas UC inflammation starts in the rectum, and
is restricted to the colon (Dobreet al.2018).
It is generally accepted that IBD is the result of overac-
tive response of mucosal immune system to the food,
environmental or infectious antigens in a genetically sus-
ceptible host (Manucet al.2016). Evidence from patients
and animal models have shown that both the innate and
cell-mediated immunities are activated by the commensal
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enteric bacteria which play crucial roles in the progres-
sion and maintenance of IBD (Mizoguchi and Mizoguchi
2010).
IBD treatment often involves induction of remission
and prevention of relapse. Corticosteroids have been ini-
tially used to induce remission, but their effectiveness is
limited, and patients under long-term corticosteroid
treatment have shown complications such as growth fail-
ure or osteopenia (Tsampalieroset al.2014). Many studies
have recommended aminosalicylates as a maintenance
treatment for IBD. Although the clinical treatment of
patients with IBD has been well established with aminos-
alicylates (Nielsen and Munck 2007), there are some pos-
sible side effects such as infection, hepatitis, leukopenia
and pancreatitis associated with this medication (Gis-
bertet al.2011; Meczkeret al.2019). Using probiotics to
modify and improve the bacterial population of the intes-
tine, and thereby reducing inflammation, is another treat-
ment method to induce or maintain remission in IBD. It
is also possible to use antibiotics to eliminate the bacteria
that potentially cause inflammation in the bowel, but
there are limitations and complications associated with
the use of antibiotics (Lewis 2014).
According to the definition of the World Health
Organization (WHO) and the Food and Agriculture
Organization of the United Nations (FAO), probiotics
are living micro-organisms which, when administered in
adequate amounts, confer a health benefit on the host
(Hotel and Cordoba 2001). Probiotics can have positive
effects on the treatment of traveller’s diarrhoea (Bae
2018), diarrhoea caused by human immunodeficiency
virus (Carteret al.2016) and recurrence of difficile colitis
(Millset al.2018). Probiotics can also inhibit the over-
growth of potentially pathogenic bacteria in the bowel
(Zhanget al.2015). Despite some conflicting results on
the therapeutic efficacy of probiotics, several studies
have shown the beneficial effects of the probiotics
Escherichia coli Nissle 1917 (EcN), Saccharomyces boular-
dii and VSL # 3 on the treatment of IBD
(Curroet al.2017; Millset al.2018). Prebiotics are defined
as non-digestible food components that beneficially
affect the host by selectively stimulating the growth
and/or activity of one or a limited number of bacteria
in gastrointestinal tract, and thus improve the host’s
condition against IBD complications (Gibson and
Roberfroid 1995). The main characteristics of prebiotics
are their resistance to digestive enzymes produced by
the human body while remaining susceptible to colonic
micro-flora fermentation (Cummings and Macfarlane
2002). Recent studies have shown the beneficial effects
of prebiotics, and immune-nutrients such as polyunsat-
urated fatty acids (PUFAs) in the remission of IBD in
human (Bernstein 2014; Ferguson 2015).
The term synbiotic refers to a product that contains
both probiotics and prebiotics. The probiotic component
of synbiotics helps the development of beneficial intesti-
nal microflora, whereas the prebiotic component inhibits
the growth of pathogenic bacteria. Synbiotics help
decrease the concentration of undesirable metabolites,
including nitrosamines, inactivate carcinogens, and pre-
vent constipation and diarrhoea in the host (Bengmark
2005; Bengmark and Martindale 2005).
The aim of this study was to review the overall efficacy
of probiotics, prebiotics and their combination (synbi-
otics) in the treatment of IBD.
Materials and Methods
The keywords ‘Inflammatory Bowel Disease’, ‘Probiotics’
and ‘Clinical trial’ were searched in the data banks;
PubMed, Web of Science, Scopus and Google Scholar.
The papers published from January 2009 to January 2020
were further assessed for their relevance based on their
title, abstract and the main text. The data extraction was
conducted by two independent researchers, and the
papers indexed in two or more databases were considered
only once. References list of all the related articles were
investigated to identify any ignored articles. A third
researcher checked the results to ensure that all the eligi-
ble articles were evaluated.
The extracted data were organized based on the
authors’ name, country, date of publication, type of clini-
cal trial, sample size, diagnostic criteria, patient’s charac-
teristics, time period of the study, genus, and species of
probiotics, probiotic dose, side effects of probiotics and
the treatment outcomes. Chi-squared test was used to
analyse the qualitative variables. Data were analysed using
SPSS software version 24.0 (IBM, Armonk, NY, USA) and
P < 005 was considered as statistically significant.
Inclusion criteria
• Articles from January 2009 to January 2020.
• Clinical trial studies.




• Reviews, meta-analyses, case reports, letters to the edi-
tor and correspondences
• Clinical feature summary
• Non-English articles
• Studies with no clear information
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Results
The initial search of the keywords generated a total of
1832 articles. Search strategy and selection of the studies
are described in Fig. 1. A total of 1519 articles were
excluded through evaluating the titles and abstracts, fol-
lowing which 74 articles were retained for detailed full-
text evaluation. Following the full-text evaluation, 21
studies, investigating the efficacy of the probiotics on IBD
treatment, fulfilled the inclusion criteria and were consid-
ered for further analysis.
Table 1 shows the summary of the characteristics and
disease distribution of the participants from articles
included in this review. The outcomes of different clinical
trials assessing the efficacy of the probiotics on the treat-
ment of IBD are shown in Table 2. Most of the studies,
which examined the effects of probiotics on the remission
of IBD, were carried out in Italy (6 out of 21 studies and
532 out of 1478 participants), followed by Iran and the
UK, respectively. The specimens including blood, serum,
stool, urine, rectal tissue biopsies and histopathology
samples were obtained from both males (54%) and
females (46%) with the mean age of 352  148 (ranging
from 1 to 78 years) (Fig. 2). Among the 21 studies, 19
examined the effect of probiotics, 1 assessed the effect of
synbiotics and 1 examined the effects of both probiotics
and synbiotics on the treatment of IBD. A total of 31 dif-
ferent probiotic species were administered once, twice or
three times daily at doses of 1 9 10 6 to 36 9 10 12 col-
ony forming units (CFUs). The average dose of probiotics
was 26 9 1013 CFUs. The frequency of probiotic bacteria
administrated in different trials for patients with IBD is
shown in Fig. 3. The most common probiotics used by
different studies were Lactobacillus acidophilus (157%),
Brevibacterium breve (9%) and Bifidobacterium longum
(79%). The majority of participants had Pancolitis
(157%), left-sided colitis (149%) and ulcerative left coli-
tis (14%). The detailed characteristics of individual trials
are shown in Table 2.
As shown in Table 2, among the 21 clinical trials, 16
trials used a combination of multi-strain probiotic bacte-
ria. One of the trials used nine types of probiotic bacte-
ria, and five trials used eight types, one trial used six
types of probiotics in combination, while one study used
four types of probiotic bacteria. Also, two clinical trials
used three types of probiotic bacteria in combination.
Search string: “IBD” and “probiotics” and “clinical trial” limited to 2009-2020 in English
language  
1,364 hits 76 hits 189 hits 203 hits
21 Duplicate papers were removed and
clinical trials assessing probiotics efficacy
on IBD in human were identified







Figure 1 Flow diagram of evaluation of the studies selected for consideration in this review.
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Moreover, four clinical trials utilized a double probiotic
agent, and four trials used only a single strain of probi-
otic bacteria. Another study used kefir to evaluate the
effect of probiotics on patients with IBD.
Generally, cases in these trials were randomly divided
into two or three groups (probiotics, placebo and/or 5-
ASA) using a random numbers sequence or by com-
puter-generated random numbers. Treatment allocation
concealment by sealed opaque envelopes was imple-
mented in one single-blinded study, and physicians were
blinded to treatment options.
Efficacy of probiotics in inducing remission in active UC
Four out of the 13 eligible trials compared probiotics
with 5-ASA compounds for remission induction of active
UC, and the other 9 trials were placebo-controlled.
Detailed study characteristics are provided in Table 2.
The four trials that compared probiotics with 5-ASAs, for
their effect in inducing remission of active UC, contained
157 patients.
Six of the trials, containing 503 patients, used VSL#3
(Ferring Pharmaceuticals Ltd.), which is a combination
of Lactobacillus, Bifidobacterium and streptococcus bacteria.
In one trial (Doreet al.2020), the need for systemic ster-
oids, hospitalization and surgery decreased to zero events
per person-year among UC patients. In another study,
VSL#3 resulted in a remission rate of 56% and a com-
bined remission/response rate of 61% (Huynhet al.2009).
Mieleet al.investigated the effects of VSL#3 on children
with UC and they found that remission was achieved in
13 (928%) patients treated with VSL#3 and 5-ASAs and
in four (364%) patients treated with placebo and 5-ASAs
(P < 0001). In total, 3 of 14 (214%) patients treated
with VSL#3 and 5-ASAs and 11 of 15 (733%) patients
treated with placebo and 5-ASAs relapsed within 1 year
of follow-up (P = 0014) (Mieleet al.2009). Wildt et al.
reported the higher efficacy of probiotics over placebo in
terms of reducing relapses (P = 037) and longer remis-
sion periods (P = 0683). In this study, no significant
clinical benefit was seen for probiotics compared to pla-
cebo for maintaining remission in patients with left-sided
ulcerative colitis (Wildt et al. 2011). Amiriani et al. exam-
ined the effects of the probiotics on mitigating the UC
symptoms in patients with UC. In this trial, a significant
decrease was seen in the intervention group
(456  256) vs. the placebo group (654  247)
(P < 005). Response to treatment was seen in 643% of
the treatment group vs. 47% in the placebo group
(p = 018). Also, response to treatment was observed in
909% of patients with UC for more than 5 years com-
pared to 444% of the individuals in the control group
(P = 001) (Amiriani et al. 2020). The diagnosis of UC in
three trials (Huynh et al. 2009; Wildt et al. 2011; Amiri-
ani et al. 2020) was based on the Simple Clinical Colitis
Table 1 Background characteristics of the patients in studies included in this review
Disease distribution n % Previous treatment n %
Small bowel disease 91 61 Prednisone 48 32
Colonic disease 109 73 Prednisolone 8 05
Ileal disease 22 14 Azathioprine/6-mercaptopurine 38 25
Ileocolonic disease 66 44 Methotrexate 2 01
Distal proctitis 5 03 Infliximab 2 01
Ulcerative left colitis 220 14 Mesalamine 145 98
Pancolitis 233 157 Mesalazine 151 102
Proctosigmoid disease 203 137 Balsalazide 4 02
Left-sided colitis 221 149 Sulphasalazine 20 13
Ileocolic Crohn’s 59 4 Tacrolimus 191 13
Colic Crohn’s 9 07
Crohn’s with fistulae 10 06
46%
54%
Figure 2 Percentage of IBD among male and female patients. ( )
Male; ( ) Female.
Journal of Applied Microbiology © 2020 The Society for Applied Microbiology4
The effect of probiotics on IBD A. Darb Emamie et al.
Activity Index (SCCAI) score. Olivia et al. examined the
efficacy of enema solution containing 1010 CFU of Lacto-
bacillus reuteri ATCC 55730 on remission induction in
children with active distal UC. Disease activity was
assessed using the Mayo Disease Activity Index (DAI),
endoscopic and histological analysis. Moreover, RT-PCR
was carried out to check IL-1b and b-actin mRNA
expression. Mayo score, including clinical and endoscopic
features, was decreased significantly in the L. reuteri
group compared with placebo (P < 001). Furthermore,
histological score significantly dropped only in the L. reu-
teri group (P < 001). In the post-trial evaluation of
mucosal cytokine expression levels, IL-10 significantly
increased (P < 001) only in the L. reuteri-treated group,
whereas IL-1b, TNF-a and IL-8 significantly decreased
(P < 001) (Oliva et al. 2012).
In the trials that were conducted on UC patients, the
criteria such as quality of life (QOL) Questionnaire and
full blood counts, renal, and liver function, C-reactive
protein (CRP), erythrocyte sedimentation rate (ESR), fae-
cal calprotectin (FCAL), serum cytokine profiling, rectal
tissue microbial profiling, PCR and qPCR, haemoglobin
(Hgb), white blood cell (WBC) count, albumin and faecal
organic acids were measured.
Two, out of 21, trials (Bourreille et al. 2013; Matsuoka
et al. 2018) showed no significant effect for probiotics
regarding the remission of UC and CD among patients.
In addition, no major adverse events were reported
among patients, assigned to probiotics or 5-ASAs. In one
trial (Matsuoka et al. 2018), individuals had avascular
necrosis of bilateral femoral head (one patient in the pla-
cebo group), surgical removal of granuloma in the throat
(one patient in the probiotics group) and pulmonary
thromboembolism (one patient in the placebo group).
Efficacy of probiotics in inducing remission in active CD
In our literature search, we found four trials, totally con-
taining 370 patients, which reported the efficacy of probi-
otics vs. placebo and/or 5-ASAs on inducing remission of
active CD. In these studies, the CD Activity Index
(CDAI) scores and European Crohn’s and Colitis Organi-
zation (ECCO) were used as diagnostic criteria. Detailed



















































































































































































Figure 3 The frequency of probiotics used in different trials for patients with IBD.
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In one study (Steed et al. 2010), the consumption of B.
longum and Synergy 1 (as a synbiotic) improved clinical
outcomes with reductions in both CDAI (P = 0020) and
histological scores (P = 0018). On the other hand, the
use of probiotics alone had no significant changes in CD
patients (P> 005) (Bjarnason et al. 2019). In another
trial (Bourreille et al. 2013), S. boulardii was introduced
as a safe and well-tolerated probiotic, but did not have
any beneficial effects on CD remission after steroid or
salicylate therapies. Moreover, CRP, ESR, FCAL, microbi-
ological analysis of tissue biopsies and histopathology
indexes, as well as ELISA and qPCR of the pro-inflamma-
tory cytokines in mucosal tissue were investigated for fur-
ther understanding of the probiotics and synbiotics
effects. One trial conducted by Marushko et al. on chil-
dren with chronic non-specific non-UC (CNNC), com-
pared the effects of immuno-nutrients, as well as
probiotics, prebiotics and PUFAs, with conventional ther-
apy (including 5-ASAs and steroids) on remission induc-
tion of CNNC. Prebiotics used in this study were inulin-
type prebiotics that contains fructans. DAI score, as well
as mucosal inflammation, decreased in infants treated
with immune-nutrients and conventional therapy. Fur-
thermore, immuno-nutrients improved the clinical mani-
festation of the disease, reduced disease activity index and
mucosal inflammation in infants with CNNC, decreased
the expression levels of pro-inflammatory cytokines while
decreased the levels of anti-inflammatory cytokines
involved in the mechanisms of IBD. The immuno-nutri-
ents also increased the indigenous bacterial count. No
serious adverse events were observed in these trials.
Efficacy of probiotics in inducing remission in patients
with IBD
In five studies, containing 667 patients, effects of probi-
otics were compared with 5-ASA compounds on the
remission of types of IBD. The diagnosis of IBD in these
studies was made according to the DAI and the Western
Ontario, and McMaster Universities Arthritis (WOMAC)
index. One of these studies used EcN on 48 healthy vol-
unteers and showed that the combination of EcN and
mesalamine has no considerable effects on the survival of
EcN, and the difference between the two groups was not
statistically significant (P > 005). Only one serious
adverse event was reported in a volunteer in the mesala-
mine group, who developed diarrhoea, fever and haema-
tochezia on the day 7 of the investigational phase, when
the administration of EcN plus mesalamine was ended.
Tomasello et al. investigated the effects of a combination
of Lactobacillus spp., Enterococcus faecium and S. boulardii
in IBD patients with extra-intestinal involvement and
they found that probiotics improved the clinical response
to standard therapy and reduce the need for corticos-
teroids (P < 005) (Tomasello et al.2015).
Shadnoush et al.(2013) investigated and compared the
serum levels of different pro-inflammatory cytokines fol-
lowing the administration of probiotic yoghurt. They
found that probiotic yoghurt consumption significantly
decreased the serum levels of IL-1b, TNF-a and CRP
among patients with IBD in comparison to the healthy
control group (P < 005). Also, in another study, con-
ducted by these same authors (Shadnoush et al.2015), the
mean numbers of Lactobacillus (P < 0001), Bifidobac-
terium (P < 0001) and Bacteroides (P < 001) significantly
increased in the intestine and colon of individuals consum-
ing probiotic yoghurt, compared to the group consuming
plain yoghurt. Yilmaz et al. reported that kefir modulates
gut microbiota, and regular consumption of this product
improves the patient’s QOL in the short term. They found
that the faecal load of Lactobacillus spp. was between 104
and 109 CFU per g among all the participants in the treat-
ment group Furthermore, the Lactobacillus kefiri load in
the stool of 17 cases was measured to be between 104 and
106 CFU per g. In this study, there was a significant
decrease in the ESR and CRP levels, a significant increase
in the Hgb level, and for the last 2 weeks of treatment,
there was a significant decrease in the bloating scores
(P = 0012), and a significant increase in feeling good
scores (P = 0032) (Yilmaz et al.2019). In these studies,
Hgb, CRP and ESR were calculated before and after the
probiotic treatment and some laboratory indexes such as
TNF-a, IL-6, IL-1b, IL-10 and CRP were measured by Taq-
man real-time PCR to the estimate the effect of the probi-
otic bacteria on IBD. Moreover, culture and Vitek MS
MALDI-TOF mass spectrometry were performed on the
bacterial isolates for the Lactobacillus spp. identification.
Discussion
At the present moment, there are no standard medical
therapies that can cure the two main types of IBD, UC
and CD. However, there are treatments that can reduce
and/or control the associated risk of cancer in the bowel
(van Bodegraven and Mulder 2006). Unfortunately, sev-
eral studies have reported side effects for the medicals
used in the management of IBD after long time follow-
up (Frandsen et al.2002). Researchers are looking for
alternative therapy or supplement to improve remission
in IBD. In recent years, the interest in microbiota-based
IBD therapy has gained more popularity, due in part to
having fewer adverse effects than traditional therapies
(Khan et al.2019). This systematic review was undertaken
to evaluate the consequences of clinical trials, assessing
the efficacy of probiotics on IBD treatment over the past
several years (Ghouri et al.2014). In the last years, several
Journal of Applied Microbiology © 2020 The Society for Applied Microbiology10
The effect of probiotics on IBD A. Darb Emamie et al.
studies have shown beneficial effects of different probiotic
preparations in inducing and maintaining remission in
adults and children with IBD, although there are two
studies which have shown no beneficial effects for probi-
otics in this regard, either alone or in combination with
synbiotics (Miele et al.2009; Sood et al.2009; Bourreille
et al.2013; Matsuoka et al.2018). A Cochrane review has
shown that there is no evidence to support the beneficial
effects of probiotics over placebo in inducing remission
in IBD (Kaur et al.2020). Discrepancies in the responsive-
ness to probiotic treatments might be due to differences
in the characteristics of the hosts (age, gender, lifestyle),
dosing regimens, duration of use, disease severity, single
or multi-strain formulation, delivery modes, etc. involved
in each study, which require further detailed investiga-
tions to match these variables and conclude a more com-
prehensive result. Among the 21 clinical trials, 16 applied
multi-species probiotics and 4 trials used mono-species
probiotics. Many properties of probiotics are strain-speci-
fic, and it is possible that multi-species probiotics be
more efficient than mono-species in the treatment of cer-
tain clinical conditions due to, for example, enhanced
chance of colonization, symbiosis and synergy between
different strains and variety diverse production of antimi-
crobial compounds (Mezzasalma et al.2016). Although
there are conflicting data regarding the effects of probi-
otics on IBD treatment (Joeres-Nguyen-Xuan et al.2010;
Iheozor-Ejiofor et al.2020), several studies have shown
that combination of probiotics with conventional thera-
pies such as mesalamine or 5-ASA, significantly enhance
the overall outcome on IBD treatment, improve the bene-
ficial effects on the gut function, reduce the need for
occasional corticosteroid therapy and induce IBD remis-
sion through synergy with the anti-inflammatory effect of
5-ASA compounds (Marushko 2013; Tomasello
et al.2015; Palumbo et al.2016). 5-ASA compounds inhi-
bit the production of inflammatory mediators such as
leukotrienes, prostaglandins, platelet-activating factor and
free radicals, all of which have roles in the pathogenesis
of IBD (Wallace et al.1999).
The six extensive studies in our review (Huynh
et al.2009; Miele et al.2009; Sood et al.2009; Ng
et al.2010; Tursi et al.2010; Amiriani et al.2020) showed
that the probiotic cocktail VSL#3 could successfully
induce IBD remission among patients. Moreover, two tri-
als (Sood et al.2009; Tursi et al.2010) supported the idea
that the use of VSL#3 in conjunction with mesalamine or
immunosuppressant improves symptoms among patients
who have not responded to mesalamine alone. Several
clinical studies have shown the efficacy of VSL#3 in
inducing and maintaining remission among IBD patients
(Bibiloni et al.2005; Park et al.2011). It is possible that
VSL#3 may act in synergy with, or perhaps augment, the
action of standard therapies due to the strain-specific
properties of its probiotic mixture which might influence
the efficacy of treatment in different cases and situations.
In addition, probiotics are considered as useful nutri-
tional supplements and their continuous ingestion might
stably improve the QOL among patients with IBD. In a
clinical trial in 2018, Yilmaz et al. assessed the effects of
kefir consumption on the QOL of IBD patients. Com-
pared to the control group, abdominal pain score
(P = 0049) and feeling good score (P = 0019) were
improved in the probiotic consuming group (Yılmaz
et al.2019). However, a similar analysis by Zocco
et al.(2006) showed no significant differences between the
probiotic and placebo-treated IBD patients.
The optimal probiotic combination and dose for the
treatment of different disease conditions have not been
specified yet. However, it is generally accepted that 108–
109 CFU per g probiotic should be consumed daily to deli-
ver the minimum concentration of 106 viable cells into the
intestine to exert positive effects on the host (Knorr 1998;
Neffe-Skocinska et al.2018). In different trials assessed in
this review, probiotics were administered once, twice or
three times daily at doses of 1 9 106 to 36 9 1012 CFU.
Overall, according to the treatment results among IBD
patients, the best-recommended dose was an average of
≥109 CFU per g, showing efficacy in remission induction
and a decrease in relapse and complication rate. Some
studies have shown that a higher or lower probiotic dose
than 109 CFU per g is only effective in increasing the QOL
and response to general symptoms (Lorenzo-Zu~niga
et al.2014). On the other hand, all the probiotics’ effects on
human health do not seem to be associated with the viabil-
ity of the bacteria, since even the dead cells or the probi-
otic-derived DNA have shown the ability to ameliorate
significant health problems (Lammers et al.2003; Rach-
milewitz et al.2004; Lahtinen 2012).
It is difficult to discuss the supremacy of different pro-
biotic species/strains since, due to the strain-specific
properties of probiotics and different categories of
patients, a specific probiotic might not be appropriate in
all patients (Zocco et al.2006; Darbandi et al.2020). Most
probiotic products contain species from Lactobacillus and
Bifidobacterium genera which modulate the gut microbial
population and increase intestinal barrier function
(Kleerebezem and Vaughan 2009; Li et al.2016). The
effect of probiotics on the gut microbiota of patients has
been reported (Marushko 2013; Shadnoush et al.2015;
Yılmaz et al.2019). Shadnoush, in 2015, indicated that the
consumption of the probiotic yogurt by IBD patients
increases the number of helpful bacteria such as of Bifi-
dobacterium and Lactobacillus, and decreases the stool
load of Bacteroides (Shadnoush et al.2015). It is believed
that probiotics can induce changes in the intestinal
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microbiota and stabilize the beneficial microbial popula-
tion by competition with pathogenic bacteria for nutri-
ents and adhesion sites, and production of different
metabolites. Yoshimatsu et al. demonstrated that probi-
otic therapy was potentially most beneficial for patients
that initially had cluster I microflora rather than cluster
II. It has been demonstrated that specific cluster types of
intestinal microbiota influence the responsiveness to pro-
biotic therapy (Yoshimatsu et al.2015). It is shown that
the interaction between probiotics and toll-like receptors
(TLRs) of enterocytes exerts its avails predominantly on
the innate immune system (Llewellyn and Foey 2017).
The imunomodulatory properties of probiotics may be
due to the bioactive compounds and secondary metabo-
lites produced during the fermentation process (Braat
et al.2006). Moreover, probiotics can reduce or repair
intestinal permeability leading to a reduced interaction
between the antigens of pathogenic bacteria and the
intestinal lumen of the host, which reduce the inflamma-
tory response in the lumen (Santos et al.2003). It has
been reported that probiotics can modulate the function
of immune cells such as T and B cells, dendritic cells
(DCs) and cytokines which have a direct influence on
human health and immune-mediated diseases (Ng
et al.2010; Dargahi et al.2019). One study has reported
that probiotics significantly reduce TLR-4 and IL-1b
levels and significantly increase mucosal IL-10 levels
(D’Inca et al.2011). Since probiotics’ effects are strain-
specific, each specific probiotic induces a unique profile
of cytokines secreted by immune cells such as lympho-
cytes, enterocytes or DCs (Azad et al.2018). Several ran-
domized clinical trials (RCTs) have evaluated the effects
of administering probiotics on the clinical scores of IBD
patients (Sood et al.2009; Marushko 2013). According to
the literature search, two trials showed side effects for
probiotic consumption (Huynh et al.2009; Matsuoka
et al.2018). Probiotic administration has shown a good
safety profile among patients with only a low rate of bac-
teraemia associated with the Lactobacillus and Bifidobac-
terium (approximately 005–04%) which has been seen
in elderly/non-elderly patients with concomitant
immunosuppressive therapy (Borriello et al.2003). Probi-
otics, specifically VSL#3 and Lactobacillus spp., are shown
to have significant health effects among children with an
age range 2–21 years who have been diagnosed with IBD
(CD and UC) (P < 001) (Ganji-Arjenaki and Rafieian-
Kopaei 2018). Huynh et al. demonstrated a decrease in
the SCCAI score, ESR, CRP, serum interferon levels,
Mayo endoscopy score for UC, as well as a decreasing
trend for TNF levels with a corresponding increase in the
Hgb and HCT levels among patients who responded to
VSL#3 treatment. Sixty-seven per cent of the IBD patients
in remission demonstrated a change in their microbial
profile with a Dice’s similarity coefficient (Huynh
et al.2009). Considering the occurrence of IBD in infants
and very young children, it is noted that genetic factors
are basic and important elements in this event (Kelsen
et al.2015; Chandrakasan et al.2017). Despite extensive
studies showing the effects of probiotics on the induction
and maintenance of remission in UC, the benefits of pro-
biotics in CD are less convincing. Shen et al.(2005) pub-
lished a systematic review with meta-analysis of RCTs
that showed therapeutic benefits associated with the use
of probiotics among UC, and pouchitis patients, but no
such effects were noted in CD. Among the four clinical
trials reporting the efficacy of probiotics vs. placebo and/
or 5-ASAs in terms of inducing remission of active CD,
two trials used a single probiotic agent and the other
three trials used multi-species probiotics or a combina-
tion of probiotics and synbiotics (Steed et al.2010; Bour-
reille et al.2013; Bjarnason et al.2019; Dore et al.2020).
Many studies have shown that a mixture of probiotics or
probiotic–synbiotic combinations could improve remis-
sion in CD and clinical symptoms among patients receiv-
ing the therapy. For example, Steed et al. showed that the
co-administration of synbiotics and probiotics induce a
significant reduction in both CD activity index
(P = 002), and histological scores (P = 0018), as well as
an increase in the proliferation of mucosal Bifidobacteria
(Steed et al.2010).
Conclusions
According to the literature review, the use of probiotics
as food supplements can induce anti-inflammatory reac-
tions, balance the intestinal homeostasis, improve the
individuals’ QOL, and induce and maintain remission in
patients with IBD. The efficacy of probiotics in remission
induction is more extensively reported by different stud-
ies in UC rather than CD. Small study populations, a
short length of patients’ follow-up and the lack of dose-
response analyses are significant limitations in interpret-
ing the effects of probiotics in inducing remission in CD.
Larger well-designed RCTs are needed to further deter-
mine whether probiotics and/or synbiotics are of clear
benefit for remission in both UC and CD. Understanding
the aetiology of IBD, the cellular and molecular mecha-
nisms of its development, as well as the functions of dif-
ferent probiotic strains can help the selection of
appropriate probiotic strains for specific IBD patients.
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